CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of...
Phase 1, Phase 2
Cleveland, Ohio, United States and 20 other locations
and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + tram...
Phase 3
Cleveland, Ohio, United States and 34 other locations
efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...
Phase 3
Cleveland, Ohio, United States of America and 49 other locations
participants with a type of skin cancer known as melanoma.The objective of this study is to see if the combination of fianlimab and cemipli...
Phase 2, Phase 3
Cleveland, Ohio, United States and 12 other locations
antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...
Phase 2, Phase 3
Cleveland, Ohio, United States and 65 other locations
to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...
Phase 3
Cleveland, Ohio, United States and 171 other locations
not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma...
Phase 3
Cleveland, Ohio, United States and 189 other locations
and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recur...
Phase 3
Cleveland, Ohio, United States and 128 other locations
treatment compared to pembrolizumab in patients that have had melanoma removal surgery but are still at high risk for the recurrence of the...
Phase 3
Cleveland, Ohio, United States and 206 other locations
(PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma...
Phase 2
Cleveland, Ohio, United States and 56 other locations
Clinical trials
Research sites
Resources
Legal